The combination of a SERM, Arzoxifene or Acolbifene, and the rexinoid, LG100268, synergize in the prevention and treatment of mammary tumors in a MMTV-Neu mouse model of estrogen receptor negative breast cancer.

被引：0
|
作者：
Liby, K
Rendi, M
Suh, N
Royce, D
Williams, C
Risingsong, R
Lamph, W
Labrie, F
Krajewski, S
Xu, XX
Kim, HT
Brown, P
Sporn, MB
机构：
[1] Dartmouth Coll Sch Med, Hanover, NH USA
[2] Ligand Pharmaceut Inc, San Diego, CA USA
[3] Univ Laval, Med Ctr, Quebec City, PQ, Canada
[4] Burnham Inst, La Jolla, CA 92037 USA
[5] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Baylor Coll Med, Houston, TX 77030 USA
来源：
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2005年 / 14卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2760S / 2760S
页数：1
相关论文
共 8 条
  • [1] The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor - Negative model of breast cancer
    Liby, Karen
    Rendi, Mara
    Suh, Nanjoo
    Royce, Darlene B.
    Risingsong, Renee
    Williams, Charlotte R.
    Lamph, William
    Labrie, Fernand
    Krajewski, Stan
    Xu, Xiaochun
    Kim, Heetae
    Sporn, Michael B.
    CLINICAL CANCER RESEARCH, 2006, 12 (19) : 5902 - 5909
  • [2] The SERM, arzoxifene and the rexinoid, LG100268 synergizeto promote apoptosis in estrogen receptor positive and negative breast cancer cells.
    Farris, MR
    Suh, N
    Heiss, E
    Place, A
    Sporn, MB
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2002, 11 (10) : 1192S - 1192S
  • [3] The rexinoid LG100268 modulates immune cell populations in mammary gland tumors of MMTV-neu mice
    Leal, Ana Sofia
    Carapellucci, Sarah
    Zydeck, Kayla
    Raychaudhuri, Nupur
    Sporn, Michael B.
    Liby, Karen T.
    CANCER RESEARCH, 2018, 78 (13)
  • [4] Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268
    Suh, N
    Lamph, WW
    Glasebrook, AL
    Grese, TA
    Palkowitz, AD
    Williams, CR
    Risingsong, R
    Farris, MR
    Heyman, RA
    Sporn, MB
    CLINICAL CANCER RESEARCH, 2002, 8 (10) : 3270 - 3275
  • [5] The rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor - Negative tumors in MMTV-erbB2 mice
    Li, Yuxin
    Zhang, Yun
    Hill, Jamal
    Shen, Qiang
    Kim, Hee-Tae
    Xu, Xiaochun
    Hilsenbeck, Susan G.
    Bissonnette, Reid P.
    Lamph, William W.
    Brown, Powel H.
    CLINICAL CANCER RESEARCH, 2007, 13 (20) : 6224 - 6231
  • [6] The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor β-dependent apoptosis in breast cancer
    Rendi, MH
    Suh, N
    Lamph, WW
    Krajewski, S
    Reed, JC
    Heyman, RA
    Berchuck, A
    Liby, K
    Risingsong, R
    Royce, DB
    Williams, CR
    Sporn, MB
    CANCER RESEARCH, 2004, 64 (10) : 3566 - 3571
  • [7] Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268
    Liby, Karen
    Risingsong, Renee
    Royce, Darlene B.
    Williams, Charlotte R.
    Yore, Mark M.
    Honda, Tadashi
    Gribble, Gordon W.
    Lamph, William W.
    Vannini, Nicola
    Sogno, Ilaria
    Albini, Adriana
    Sporn, Michael B.
    CLINICAL CANCER RESEARCH, 2008, 14 (14) : 4556 - 4563
  • [8] The EGRF receptor inhibitor Erlotinib, alone or in combination with the rexinoid LG100268, is effective for prevention in mouse models of lung and pancreatic cancer with Kras mutations
    Liby, Karen T.
    Williams, Charlotte R.
    Risingsong, Renee
    Sporn, Michael B.
    Collins, Ryan M.
    Royce, Darlene B.
    CANCER RESEARCH, 2014, 74 (19)
1